Core Viewpoint - The company is advancing its plan to issue H-shares and list on the main board of the Hong Kong Stock Exchange, aiming to raise approximately 34.33 billion HKD from the global offering [1] Group 1: H-Share Offering Details - The total number of H-shares for the global offering is set at 104 million shares before the exercise of the over-allotment option [1] - The offering includes 10.42 million shares for public sale in Hong Kong and 93.80 million shares for international sale [1] - The price per H-share is set at 34.00 HKD, with net proceeds estimated at around 34.33 billion HKD, assuming the over-allotment option is not exercised [1]

证券代码：300919 证券简称：中伟股份 公告编号：2025-123 因本次拟发行的 H 股股份的认购对象仅限于符合相关条件的境外投资者及依据中国相 关法律法规有权进行境外证券投资的境内合格投资者。因此，本公告仅为 A 股投资者及时 了解公司本次发行上市的相关信息而作出，并不构成亦不得被视为是对任何个人或实体或 境内投资者收购、购买或认购公司本次发行的 H 股的要约或要约邀请。 公司本次全球发售 H 股基础发行股数为 104,225,400 股（行使超额配售权之前），其 中，香港公开发售 10,422,600 股；国际发售 93,802,800 股。根据每股 H 股发售价 34.00 港 元计算，经扣除全球发售相关承销佣金及其他估计费用后，并假设超额配售权未获行使， 公司将收取的全球发售所得款项净额估计约为 34.3261 亿港元。 有关公司本次发行配售结果的进一步详细信息，可查询公司于 2025 年 11 月 16 日在 香港联交所网站（www.hkexnews.hk）披露的相关公告（具体披露时间以香港联交所披露 时间为准）。 特此公告。 中伟新材料股份有限公司 中伟新材料股份有限公司 关于境外上市股份（ ...

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

Group 1: Company Performance - SMIC reported a revenue of 17.162 billion yuan in Q3 2025, a year-on-year increase of 9.9%, with a net profit of 1.51 billion yuan, up 43.1% year-on-year. For the first three quarters, revenue reached 49.51 billion yuan, growing 18.2%, and net profit was 3.81 billion yuan, an increase of 41.1% year-on-year [1] - BoRui Pharma's BGM1812 injection has received clinical trial approval for weight loss indications, with no similar targeted formulations approved globally [2] - Li Zhong Group's subsidiaries received project confirmations for aluminum alloy wheels from major international automotive manufacturers, with expected total sales of approximately 1.135 billion yuan [4] Group 2: Corporate Actions - Kanda New Materials announced the termination of the acquisition of equity in North One Semiconductor due to unmet progress expectations and lack of consensus among parties [3] - Lide Man plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, aiming to enter the bioproducts industry [9] - Arctech's controlling shareholder CSIQ expects total revenue of 1.3 to 1.5 billion USD in Q4 2025, with a gross margin of 14% to 16% [6] Group 3: Market Activity - Taihe Technology's VC project phase two construction will be adjusted based on phase one market expansion, indicating some uncertainty [5] - Hezhong China has experienced significant stock price fluctuations, with a cumulative increase of 230.84% over 12 out of 13 trading days, leading to potential application for trading suspension if abnormal price increases continue [7][8]

Group 1 - The company has set the final price for its H-share issuance at HKD 34.00 per share, excluding various transaction fees [1] - The H-shares are expected to be listed and start trading on the Hong Kong Stock Exchange on November 17, 2025 [1]

Group 1 - The core point of the article is that Zhongwei Co., Ltd. has set the final price for its H-share issuance at HKD 34.00 per share, with plans to list on the Hong Kong Stock Exchange on November 17, 2025 [1] Group 2 - The company is preparing for its H-share issuance, indicating a strategic move to expand its capital base and enhance its market presence [1] - The listing on the Hong Kong Stock Exchange is a significant milestone for the company, potentially increasing its visibility and attracting more investors [1] - The final pricing of HKD 34.00 per share reflects the company's valuation and market conditions at the time of the announcement [1]

Group 1 - The company Zhongwei Co., Ltd. (300919) has announced the final price for its H-share issuance at HKD 34.00 per share [1] - The company is expected to be listed and commence trading on the main board of the Hong Kong Stock Exchange on November 17, 2025 [1]

人民财讯11月13日电，中伟股份（300919）11月13日公告，公司已确定H股发行的最终价格为每股34港 元，公司此次发行的H股预计于11月17日在香港联交所主板挂牌并开始上市交易。 ...

中伟股份：公司已确定本次H股发行的最终价格为每股34港元。 ...

证券代码：300919 证券简称：中伟股份 公告编号：2025-122 中伟新材料股份有限公司 关于境外上市股份（H股）公开发行价格的公告 因本次拟发行的 H 股股份的认购对象仅限于符合相关条件的境外投资者及依据中国相 关法律法规有权进行境外证券投资的境内合格投资者。因此，本公告仅为 A 股投资者及时 了解公司本次发行上市的相关信息而作出，并不构成亦不得被视为是对任何个人或实体或境 内投资者收购、购买或认购公司本次发行的 H 股的要约或要约邀请。 公司已确定本次 H 股发行的最终价格为每股 34.00 港元（不包括 1%经纪佣金、0.0027% 香港证券及期货事务监察委员会交易征费、0.00565%香港联交所交易费及 0.00015%香港会 计及财务汇报局交易征费）。 公司本次发行的H股预计于2025年11月17日在香港联交所主板挂牌并开始上市交易。 特此公告。 中伟新材料股份有限公司 董事会 二〇二五年十一月十三日 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 中伟新材料股份有限公司（以下简称"公司"）正在进行发行境外上市股份 H 股（以下 简称"H 股"）并在 ...